drugset / Trial / NCT05510895
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
Phase 2
Completed
2 enrolled
AIO-Studien-gGmbH
Merck Serono GmbH, Germany · collabPierre Fabre Pharma GmbH · collabUniversitätsklinikum Hamburg-Eppendorf · collab
NaSingle-groupOpen-labelTreatment
Summary
AIO-KRK-0420 NeoBRAF is a single arm, multicenter, phase II trial with neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-07-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | 45 mg | — |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | — |
| Subject | Encorafenib | Small molecule | 300 mg | — |